Thus, subsequent studies should analyse expression of SLC26A9 in CF lungs from patients with different class 1–7 mutations, as well as the effect of CFTR correctors on correcting the plasma membrane location of SLC26A9. The gene discussed is SLC26A9; the disease is cystic fibrosis.